EMPLOYMENT AGREEMENTEmployment Agreement • March 29th, 2022 • Pardes Biosciences, Inc. • Pharmaceutical preparations
This Employment Agreement (“Agreement”) is made and entered into as of March 1, 2022 (the “Effective Date”) between Pardes Biosciences, Inc., a Delaware corporation (the “Company”), and Thomas
March 25, 2022 PERSONAL AND CONFIDENTIAL Uri A. Lopatin, M.D. Re: Transition and Separation Agreement and General Release of Claims Dear Uri:Personal and Confidential • March 29th, 2022 • Pardes Biosciences, Inc. • Pharmaceutical preparations • California
Effective March 1, 2022 (the “Transition Date”) you no longer serve as the Chief Executive Officer and President of the Company. This letter (this “Agreement”) provides notices that on July 31, 2022 (the “Separation Date”), your employment with Pardes Biosciences, Inc. (the “Company”) shall terminate without Cause (as defined in Section 1(d) of the Executive Severance Plan). During the period between the Transition Date and the Separation Date (the “Transition Period”), you will continue as an employee of the Company serving in the role of Chief Scientific and Strategic Advisor and your compensation and severance benefits remain unchanged through the Separation Date. The Company thanks you for your contributions, assistance and continued commitment to the Company during this transition period. Capitalized terms used in this Agreement and not otherwise defined shall have the meaning assigned to such term in the Executive Severance Plan, a copy of which is attached hereto as Exhibit A (t
CONSULTING AGREEMENTConsulting Agreement • March 29th, 2022 • Pardes Biosciences, Inc. • Pharmaceutical preparations • California
This CONSULTING AGREEMENT (this “Consulting Agreement”) is executed as of March 25, 2022 to be effective as of the first day following the Separation Date (as defined in the Separation Agreement) (the “Effective Date”) but contingent upon, and assuming that, both the Separation Agreement has become effective and not revoked and the Supplemental Release (attached to the Separation Agreement as Exhibit B) has become effective, by and between Pardes Biosciences, Inc., a Delaware corporation (“Company”), and Uri A. Lopatin, M.D., a California resident (the “Consultant”). This Consulting Agreement is being entered into by the parties pursuant to that certain Transition and Separation Agreement and General Release of Claims dated as of March 25, 2022 (the “Separation Agreement”) and is Exhibit C to such Separation Agreement. Each capitalized term used herein and not otherwise defined shall have the meaning assigned to such term in the Separation Agreement.
